Epidemiology and clinical classification of onychomycosis

被引:108
作者
Effendy, I
Lecha, M
de Chauvin, MF
Di Chiacchio, N
Baran, R
机构
[1] Stadt Kliniken Bielefeld, Klinikum Rosenhohe, Hautklin, D-33647 Bielefeld, Germany
[2] Hosp Clin Barcelona, Serv Dermatol, Barcelona, Spain
[3] St Louis Hosp, Mycol Lab, Paris, France
[4] Hosp Servidor Publ Municipal Sao Paulo, Sao Paulo, Brazil
[5] Nail Dis Ctr, Cannes, France
关键词
causative agent; epidemiology; nail matrix; onychomycosis; treatment strategy;
D O I
10.1111/j.1468-3083.2005.01281.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objectives To review recent data - what is new in the epidemiology of onychomycoses? To identify the most relevant diagnostic criteria for effective therapy. Methods The preliminary results of the European Onychomycosis Observatory (EUROO) study were analysed. In this international study, physicians completed questionnaires concerning patient profile and the disease. Results One of the most interesting novel findings was that sampling requests were often not made [only 3.4% of general physicians (GPs) and 39.6% of dermatologists]. This means that no information about causative agent(s) was available, hindering appropriate treatment choice. Furthermore, contrary to previous findings, 70.7% of participants did not practice sports. Lastly, these preliminary findings showed that treatment strategy depends largely on the type of treating physician, with GPs preferring monotherapy and dermatologists preferring combination therapy. Conclusions A consensus was reached that treatment strategy should depend on the severity of nail involvement and the causative fungus. It is thus important to promote the importance of sampling. To simplify the choice of an appropriate treatment, onychomycosis may be divided into just two clinical groups: onychomycosis with and without nail matrix area involvement. However, the distinct clinical findings (number and type of affected nails, multimorbidity, drug interaction, etc.) in each individual case must be taken into account to ensure an appropriate treatment decision.
引用
收藏
页码:8 / 12
页数:5
相关论文
共 12 条
[1]   High prevalence of foot diseases in Europe: results of the Achilles Project [J].
Burzykowski, T ;
Molenberghs, G ;
Abeck, D ;
Haneke, E ;
Hay, R ;
Katsambas, A ;
Roseeuw, D ;
van de Kerkhof, P ;
van Aelst, R ;
Marynissen, G .
MYCOSES, 2003, 46 (11-12) :496-505
[2]  
Chabasse D, 2003, ANN DERMATOL VENER, V130, P1222
[3]  
EFFENDY I, 1995, J EUR ACAD DERMATOL, V4, pS3
[4]   Epidemiology, clinical presentation and diagnosis of onychomycosis [J].
Faergemann, J ;
Baran, R .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 :1-4
[5]  
Gill D, 1999, Australas J Dermatol, V40, P6, DOI 10.1046/j.1440-0960.1999.00308.x
[6]   Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: A multicenter Canadian survey of 15,000 patients [J].
Gupta, AK ;
Jain, HC ;
Lynde, CY ;
MacDonald, P ;
Cooper, EA ;
Summerbell, RC .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (02) :244-248
[7]   Achilles foot-screening project: background, objectives and design [J].
Haneke, E .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 1999, 12 :S2-S5
[8]   Achilles foot screening project: preliminary results of patients screened by dermatologists [J].
Roseeuw, D .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 1999, 12 :S6-S9
[9]  
SAIS G, 1995, BRIT J DERMATOL, V132, P758, DOI 10.1111/j.1365-2133.1995.tb00722.x
[10]   Risk factors associated with onychomycosis [J].
Sigurgeirsson, B ;
Steingrímsson, O .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2004, 18 (01) :48-51